DENTSPLY SIRONA Inc. XRAY
2 targets with a reported result
Releases of the last 3 yearsThe numbers XRAY said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Diluted EPS (company-defined) Fiscal 2026 |
Given $1.40 to $1.50 release Feb 26, 2026
Kept $1.40 to $1.50 release May 5, 2026
Lowered $1.20 to $1.30 release Nov 5, 2026
|
– | No standard number | |
The company's wordsFY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50 (1) release Feb 26, 2026 The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50. release May 5, 2026 Updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30 release Nov 5, 2026 | ||||
| Revenue Fiscal 2026 |
Given $3.50B to $3.60B release Feb 26, 2026
Kept $3.50B to $3.60B release May 5, 2026
|
– | Not reported yet | |
The company's wordsFY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50 (1) release Feb 26, 2026 The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50. release May 5, 2026 | ||||
| Diluted EPS (company-defined) Fiscal 2025 (ended Dec 31, 2025) |
Given $1.80 to $2.00 release Feb 27, 2025
Kept $1.80 to $2.00 release May 8, 2025
Kept $1.80 to $2.00 release Aug 7, 2025
Lowered $1.60 release Nov 6, 2025
|
– | No standard number | |
The company's wordsFY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (2.0%); adjusted EPS of $1.80 to $2.00 (1) release Feb 27, 2025 The Company is maintaining its 2025 outlook for organic sales in the range of down (4.0%) to (2.0%), and adjusted EPS in the range of $1.80 to $2.00. release May 8, 2025 The Company is maintaining its 2025 outlook for net sales of $3.60 billion to $3.70 billion, down (4.0%) to (2.0%) on a constant currency basis, and adjusted EPS in the range of $1.80 to $2.00. release Aug 7, 2025 Updated 2025 Outlook … Adjusted EPS is expected to be approximately $1.60. release Nov 6, 2025 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $3.50B to $3.60B release Feb 27, 2025
Raised $3.60B to $3.70B release Aug 7, 2025
|
$3.68B 10-K filed 2026-02-26 |
Within the range | |
The company's wordsFY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (2.0%); adjusted EPS of $1.80 to $2.00 (1) release Feb 27, 2025 The Company is maintaining its 2025 outlook for net sales of $3.60 billion to $3.70 billion, down (4.0%) to (2.0%) on a constant currency basis, and adjusted EPS in the range of $1.80 to $2.00. release Aug 7, 2025 | ||||
| Diluted EPS (company-defined) Fiscal 2024 (ended Dec 31, 2024) |
Given $2.00 to $2.10 release Feb 29, 2024
Kept $2.00 to $2.10 release May 2, 2024
Lowered $1.96 to $2.02 release Jul 31, 2024
Lowered $1.82 to $1.86 release Nov 7, 2024
|
– | No standard number | |
The company's wordsFY24 outlook: organic sales flat to up 1.5%; adjusted EPS of $2.00 to $2.10 release Feb 29, 2024 The Company is maintaining its 2024 outlook for organic sales growth in the range of flat to up 1.5%, and adjusted EPS in the range of $2.00 to $2.10. release May 2, 2024 Revised FY24 outlook: organic sales down (1%) to flat (previously flat to up 1.5%); adjusted EPS of $1.96 to $2.02 (previously $2.00 to $2.10) release Jul 31, 2024 Revised FY24 outlook: expect organic sales of (3.5%) to (2.5%) (previously (1%) to flat); adjusted EPS of $1.82 to $1.86 (previously $1.96 to $2.02) release Nov 7, 2024 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $3.96B to $4.02B release Feb 29, 2024
|
$3.79B 10-K filed 2025-02-27 |
Below the range | |
The company's wordsThe 2024 outlook includes anticipated net sales in the range of $3.96 billion to $4.02 billion, flat to up 1.5% on an organic basis. release Feb 29, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (14 releases since 2024-01-09), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/XRAY/export.csv") into a cell.